Annual Report 2024

MANAGEMENT DISCUSSION AND ANALYSIS 12 The United Laboratories International Holdings Limited Annual Report 2024 Finished Products During the year, the external sales of finished products was RMB4,727.6 million, representing a year-on-year decrease of 5.9%. Endocrine metabolism The main products include 優思靈 USLIN ® (Human Insulin Injection (N/R/30R/50R)), 聯邦優樂靈 ® USLEN ® (Insulin Glargine Injection), 聯邦優倍靈 ® UBLIN ® (Insulin Aspart/Insulin Aspart 30 Injection), and 聯邦 ® 滅特尼 ® (Glipizide Tablets). During the year, diabetes series recorded total gross sales of RMB1,248.3 million, representing a year-on-year increase of 9.5%. In April 2024, all insulin products of the Group won the bidding as Category A in the National Centralised Procurement of Pharmaceuticals (specialising renewal in insulin). The basic purchasing volume has increased significantly by 52.5%. At the same time, all the Group’s bidding products in category A will obtain allocated remaining volume. Benefitting from this bidding, the Group was able to rapidly make up for the price by volume for the relevant products, and the sales scale and market share continued to increase. During the year, sales volume of insulin analogs increased by 41.0% year-on-year, maintaining a high growth rate. Anti-infection The main products include 聯邦他唑仙 ® (Piperacillin Sodium Tazobactam Sodium for Injection), 聯邦 ® 阿莫仙 ® (Amoxicillin Capsules/Granules), 強力阿莫仙 ® (Potassium Amoxicillin Clavulanate for Injection, Potassium Amoxicillin Clavulanate Tablets/Dry Suspensions), and 聯邦倍能安 ® (Imipenem Cestastatin Sodium for Injection), among others. During the year, sales of anti-infection products (for human use) decreased by 23.6% to RMB1,797.4 million. Other human-use finished products The main products include ophthalmic drugs, topical dermatological drugs, and neurological drugs.